Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (August 2025)
30 slides from Blis Technologies's shareholder meeting presentation, Aug 21, 2025
Slide 1: Annual Shareholder Meeting 2025
ANNUAL SHAREHOLDER MEETING 2025 21 AUGUST 2025
Slide 2: Attendees Question & Voting Process
ATTENDEES QUESTION & VOTING PROCESS VOTING CARD QUESTION BOX 2
Slide 3: Meeting Agenda
MEETING AGENDA BUSINESS OF THE MEETING CHAIR’S ADDRESS • Geoff Plunket CHIEF EXECUTIVE OFFICER’S ADDRESS • Scott Johnson ORDINARY RESOLUTIONS • That Amelia (Aimee) McCammon be re-elected as a Director • That Dame Alison Stewart be re-elected as a Director • Directors authorised to fix the auditors r
Slide 4: Board of Directors
BOARD OF DIRECTORS GEOFFREY (GEOFF) AMELIA (AIMEE) DR BARRY DAME ALISON ANITA PLUNKET MCCAMMON RICHARDSON STEWART JOHANSEN Chair, Independent Independent Independent Independent Non-executive Director non-executive Director non-executive Director non-executive Director non-executive Director — — — —
Slide 5: FY25 Summary
FY25 SUMMARY 12.6M REVENUE 1.0M EBITDA 0.8M NPAT NO DIVIDEND TO BE DECLARED FOR FY25. 10% on prior year 26% on prior year 30% on prior year 5
Slide 6: CEO Address
CEO ADDRESS SCOTT JOHNSON Chief Executive Officer 6
Slide 7: Leadership Team
LEADERSHIP TEAM Left to right: ASHLEIGH CHILDS People & Culture MELISSA DRYSDALE Head of Quality RICHARD WINGHAM Chief Financial Officer (CFO) SCOTT JOHNSON Chief Executive Officer (CEO) JENNIFER WALKER Chief Revenue Officer (CRO) DR JOHN HALE Chief Technology Officer (CTO) 7
Slide 8: Global Market Snapshot
GLOBAL MARKET SNAPSHOT PROBIOTIC DIETARY GLOBAL PROBIOTIC DIETARY SUPPLEMENTS SUPPLEMENT MARKET MARKET SHARE BY REGION (2024) Market Size in USD Billion CAGR 11.96% USD 22.01 B 10% 5.4% 22% Europe North America USD 12.51 B Asia-Pacific Rest of World 37.6% 25% Middle East & Africa 2025 2030 Source: M
Slide 9: FY25 Financial Performance
FY25 FINANCIAL PERFORMANCE REVENUE EBITDA NPAT 10% on prior year 26% on prior year 30% on prior year $m $m $m 14.0 1.2 1.5 12.6 1.0 11.5 1.0 12.0 0.8 1.0 0.8 10.2 0.8 0.6 10.0 0.6 0.5 8.0 0.4 - 0.2 6.0 - (0.5) 4.0 (0.2) (1.0) (0.4) 2.0 (1.5) (1.4) (0.6) (0.6) - (0.8) (2.0) 2023 2024 2025 2023 2024 2
Slide 10: FY25 Financial Performance
FY25 FINANCIAL PERFORMANCE CASH GENERATED REVENUE BY REGION REVENUE BY CHANNEL FROM OPERATIONS FY25 FY25 70% on prior year 36% 16% New Zealand EMEA 36% B2B Asia Pacific B2C $m 30% (excl. NZ) 64% 2.0 North America 1.8 18% 1.8 1.6 1.4 1.1 FY24 FY24 1.2 1.0 16% New Zealand 0.8 29% 31% EMEA 0.6 B2B 0.4
Slide 11: Revenue & Market Performance B2B
REVENUE & MARKET PERFORMANCE B2B $ 8.1M B2B B2B REVENUE (NZ$M) FY25 B2B REVENUE BY SALES CHANNEL (NZ$M) $m 9 • Ingredient down 14% slightly overall 8.0 8.1 10% Ingredients: 6.2 8 Private label: 0.8 • North America (+83%) License fee 77% and APAC (+53%) growth and royalties: 1.1 7 6.8 • Royalty stead
Slide 12: Revenue & Market Performance B2C
REVENUE & MARKET PERFORMANCE B2C $ 4.5M B2C 29% B2C REVENUE (NZ$M) FY25 B2C REVENUE BY SALES CHANNEL (NZ$M) $m 5 4.5 • 36% of total revenue 14% 4 30% (+from 31%) 3.5 3.5 NZ wholesale: 1.4 CBEC: 0.5 • Amazon USA: $2m 3 Amazon USA: 2.0 44% 12% (+30%) 2 BLIS webstore: 0.6 • BLIS Webstore: $0.6m 1 (+19%
Slide 13: IP and Market Risks
IP AND MARKET RISKS LEGAL AND SUPPLY AND TARIFFS MARKETING AGREEMENT • US: 15% tariff on finished goods • Negotiations concluded on Bluestone Pharma GmbH (April 2025 price rise on Amazon) (BSP) fermentation patent applications on July 2nd • Joint ownership agreement reached • Mutual release of claim
Slide 14: Strategic Focus & Execution
STRATEGIC FOCUS & EXECUTION CONTINUED PROBI FOCUSED PIPELINE CHINA FOCUS ON CORE: PARTNERSHIP OF CONSUMER REGULATORY K12™ & M18™ IN US REMAINS INSIGHT DRIVEN R&D PROJECT NEAR CENTRAL AND NPD PROJECTS COMPLETION 14
Slide 15: FY26 Strategic Plan
FY26 STRATEGIC PLAN OUR PURPOSE Being the best at developing probiotic solutions for the health and wellbeing of global consumers. PEOPLE PROFIT CUSTOMER OUR IMPACT Caring for our team Sustainable growth Building partnerships We are acknowledged globally as the preferred OUR VISION partner and leade
Slide 16: ESG & Culture
ESG & CULTURE B CORP ‘LEADING AT BLIS’ MYGREEN LAB: ZERO LTIs CERTIFICATION LEADERSHIP GREEN RE- FOR 6 YEARS PREPARATION PROGRAMME CERTIFICATION • To enhance shareholder value • Formalises BLIS’ commitment to responsible, sustainable growth • Requires minor constitutional change 16
Slide 17: Supply Chain
SUPPLY CHAIN RAW INGREDIENT VOLUME AND PRICING PRESSURES One-off impact in Q1 and ongoing pressure WORKING THROUGH AGREEMENT WITH ADDITIONAL FERMENTATION PARTNER TO ENSURE CUSTOMER DEMAND IS MET 17
Slide 18: 25 Year Milestone
25 YEAR MILESTONE FOUNDED IN 2000 ON PROF. JOHN TAGG’S RESEARCH ONGOING SCIENTIFIC AND MENTORING ROLE AT BLIS GLOBAL RECOGNITION OF DISCOVERY AND CONTRIBUTION 18
Slide 19: Closing and Outlook
CLOSING AND OUTLOOK UNAUDITED RESULTS FOR THE OUTLOOK QUARTER ENDING 30 JUNE 2025 (1Q26) • 1HY26 revenue of $7.5m, 25% increase on 1HY25 $ 3.5M ( 0.2M) REVENUE $ EBITDA • 1H26 positive EBITDA (inclusive of one-off costs) • FY26 full year revenue growth of 10%–15% 19
Slide 20: Questions
QUESTIONS WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder.
Slide 21: Attendees Question Process
ATTENDEES QUESTION PROCESS QUESTION BOX 21
Slide 22: Resolutions
RESOLUTIONS WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder.
Slide 23: Attendees Voting Process
ATTENDEES VOTING PROCESS VOTING CARD 23
Slide 24: Resolution 1: Re-election of Amelia (Aimee) McCammon
RESOLUTION 1 THAT AMELIA (AIMEE) MCCAMMON BE RE-ELECTED AS A DIRECTOR OF THE COMPANY. WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder. 24
Slide 25: Resolution 2: Re-election of Dame Alison Stewart
RESOLUTION 2 THAT DAME ALISON STEWART BE RE-ELECTED AS A DIRECTOR OF THE COMPANY. WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder. 25
Slide 26: Resolution 3: Auditor Remuneration
RESOLUTION 3 THAT THE DIRECTORS BE AUTHORISED TO FIX THE REMUNERATION OF THE AUDITORS FOR THE ENSUING YEAR. WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder. 26
Slide 27: Resolution 4: Amendment of the Constitution
RESOLUTION (SPECIAL) 4 AMENDMENT OF THE CONSTITUTION OF THE COMPANY. WAIT FOR THE MICROPHONE State your name and whether you are a shareholder or proxy holder. 27
Slide 28: General Business
GENERAL BUSINESS
Slide 29: Disclaimer
DISCLAIMER INFORMATION FUTURE PERFORMANCE The information in this presentation is an overview and does not contain all information necessary This presentation may contain certain ‘forward-looking statements’, for example statements to make an investment decision. It is intended to constitute a summa
Slide 30: Thank You
THANK YOU
BLIS Technologies — Shareholder Meeting (August 2025) on 6ix